Advertisement

Drug-Induced Liver Injury

  • Bing Ren
  • Arief A. SuriawinataEmail author
  • Masaki Iwai
Chapter

Abstract

Drug-induced liver injury (DILI) includes a wide range of responses following exposure to any manufactured or naturally occurring chemical compounds. DILI is a significant concern due to the increasing numbers of approved new drugs and new herbals and dietary supplements on the market. Diagnosis of DILI is challenging because no clinical, laboratory, or histologic features are specific to DILI. Accurate diagnosis requires understanding the mechanism and biochemical profiles of DILI and recognizing the histologic patterns of liver injury. The pathologist plays an essential role in the evaluation of DILI by interpreting the histologic findings and correlating with patients’ medical history and drug exposure, and by helping clinicians to confirm or rule out the drug effect or raise alternative causes for liver injury.

Keywords

Drug-induced liver injury Drug-induced hepatitis Cholestatic hepatitis 

Abbreviations

AIH

Autoimmune hepatitis

ALP

Alkaline phosphatase

ALT

Alanine aminotransferase

AST

Aspartate aminotransferase

DAIH

Drug-induced autoimmune hepatitis

DILI

Drug-induced liver injury

DILIN

Drug-Induced Liver Injury Network

GGT

Gamma-glutamyltransferase

HDSs

Herbal and dietary supplements

TBIL

Total bilirubin

ULN

Upper limit of normal

References

  1. 1.
    Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J: Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924–34, 34.e1–4.CrossRefGoogle Scholar
  2. 2.
    Williamson K, Wahl MS, Mycyk MB. Direct comparison of 20-hour IV, 36-hour oral, and 72-hour oral acetylcysteine for treatment of acute acetaminophen poisoning. Am J Ther. 2013;20:37–40.CrossRefGoogle Scholar
  3. 3.
    Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (Baltimore, MD). 2014;59:661–70.CrossRefGoogle Scholar
  4. 4.
    Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007;102:2459–63.CrossRefGoogle Scholar
  5. 5.
    Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25:1411–21.CrossRefGoogle Scholar
  6. 6.
    Yamashita YI, Imai K, Mima K, Nakagawa S, Hashimoto D, Chikamoto A, Baba H. Idiosyncratic drug-induced liver injury: a short review. Hepatol Commun. 2017;1:494–500.CrossRefGoogle Scholar
  7. 7.
    Stephens C, Lopez-Nevot MA, Ruiz-Cabello F, Ulzurrun E, Soriano G, Romero-Gomez M, Moreno-Casares A, Lucena MI, Andrade RJ. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013;8:e68111.CrossRefGoogle Scholar
  8. 8.
    Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44:116–26.CrossRefGoogle Scholar
  9. 9.
    Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, Fontana RJ, Day CP, Chinnery PF. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology (Baltimore, MD). 2010;52:1791–6.CrossRefGoogle Scholar
  10. 10.
    Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (Baltimore, MD). 2008;47:2003–9.CrossRefGoogle Scholar
  11. 11.
    Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138:2246–59.CrossRefGoogle Scholar
  12. 12.
    Sundaram V, Bjornsson ES. Drug-induced cholestasis. Hepatol Commun. 2017;1:726–35.CrossRefGoogle Scholar
  13. 13.
    Bjornsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther. 2006;79:521–8.CrossRefGoogle Scholar
  14. 14.
    Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ. Sanchez De La cuesta F: comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology (Baltimore, MD). 2001;33:123–30.CrossRefGoogle Scholar
  15. 15.
    Kleiner DE. Drug-induced liver injury: the hepatic Pathologist's approach. Gastroenterol Clin N Am. 2017;46:273–96.CrossRefGoogle Scholar
  16. 16.
    Kleiner DE. Recent advances in the histopathology of drug-induced liver injury. Surg Pathol Clin. 2018;11:297–311.CrossRefGoogle Scholar
  17. 17.
    Zhang X, Ouyang J, Thung SN. Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis. 2013;17:547–64.. vii-viiiCrossRefGoogle Scholar
  18. 18.
    de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15:103–12.. e2CrossRefGoogle Scholar
  19. 19.
    Bjornsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M, Lindor K. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology (Baltimore, MD). 2010;51:2040–8.CrossRefGoogle Scholar
  20. 20.
    Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, Lucena MI, Castiella A, Lindor K, Bjornsson E. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (Baltimore, MD). 2011;54:931–9.CrossRefGoogle Scholar
  21. 21.
    Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, Garcia-Cortes M, Fernandez MC, Pelaez G, Rodrigo L, Duran JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Munoz-Yague T, Salmeron J, Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology (Baltimore, MD). 2006;44:1581–8.CrossRefGoogle Scholar
  22. 22.
    Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000;118:422–30.CrossRefGoogle Scholar
  23. 23.
    Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62:481–92.CrossRefGoogle Scholar
  24. 24.
    Arranto AJ, Sotaniemi EA. Histologic follow-up of alpha-methyldopa-induced liver injury. Scand J Gastroenterol. 1981;16:865–72.CrossRefGoogle Scholar
  25. 25.
    Rodman JS, Deutsch DJ, Gutman SI. Methyldopa hepatitis. A report of six cases and review of the literature. Am J Med. 1976;60:941–8.CrossRefGoogle Scholar
  26. 26.
    Toghill PJ, Smith PG, Benton P, Brown RC, Matthews HL. Methyldopa liver damage. Br Med J. 1974;3:545–8.CrossRefGoogle Scholar
  27. 27.
    Timbo BB, Ross MP, McCarthy PV, Lin CT. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc. 2006;106:1966–74.CrossRefGoogle Scholar
  28. 28.
    Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, Seeff LB, Serrano J, Sherker AH, Stolz A, Talwalkar J, Vega M, Vuppalanchi R. Liver injury from herbals and dietary supplements in the U.S. drug-induced liver injury network. Hepatology (Baltimore, MD). 2014;60:1399–408.CrossRefGoogle Scholar
  29. 29.
    Rios FF, Rodrigues de Freitas LA, Codes L, Santos Junior GO, Schinoni MI, Parana R. Hepatoportal sclerosis related to the use of herbals and nutritional supplements. Causality or coincidence? Ann Hepatol. 2016;15:932–8.PubMedGoogle Scholar
  30. 30.
    Heidemann LA, Navarro VJ, Ahmad J, Hayashi PH, Stolz A, Kleiner DE, Fontana RJ. Severe acute hepatocellular injury attributed to OxyELITE pro: a case series. Dig Dis Sci. 2016;61:2741–8.CrossRefGoogle Scholar
  31. 31.
    Elsharkawy AM, McPherson S, Masson S, Burt AD, Dawson RT, Hudson M. Cholestasis secondary to anabolic steroid use in young men. BMJ (Clinical Res ed). 2012;344:e468.CrossRefGoogle Scholar
  32. 32.
    Brazeau MJ, Castaneda JL, Huitron SS, Wang J. A case report of supplement-induced hepatitis in an active duty service member. Mil Med. 2015;180:e844–6.CrossRefGoogle Scholar
  33. 33.
    Kou T, Watanabe M, Yazumi S. Hepatic failure during anabolic steroid therapy. Gastroenterology. 2012;143:e11–2.CrossRefGoogle Scholar
  34. 34.
    Davidov Y, Har-Noy O, Pappo O, Achiron A, Dolev M, Ben-Ari Z. Methylprednisolone-induced liver injury: case report and literature review. J Dig Dis. 2016;17:55–62.CrossRefGoogle Scholar
  35. 35.
    Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11:558–64.. e3CrossRefGoogle Scholar
  36. 36.
    Bjornsson ES, Gunnarsson BI, Grondal G, Jonasson JG, Einarsdottir R, Ludviksson BR, Gudbjornsson B, Olafsson S. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13:602–8.CrossRefGoogle Scholar
  37. 37.
    Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, Doyle LA. Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39:1075–84.CrossRefGoogle Scholar
  38. 38.
    Antezana A, Sigal S, Herbert J, Kister I. Natalizumab-induced hepatic injury: a case report and review of literature. Mult Scler Relat Disord. 2015;4:495–8.CrossRefGoogle Scholar
  39. 39.
    Grant LM, Kleiner DE, Conjeevaram HS, Vuppalanchi R, Lee WM. Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. Dig Dis Sci. 2013;58:1415–21.CrossRefGoogle Scholar
  40. 40.
    Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450–9.CrossRefGoogle Scholar
  41. 41.
    Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology (Baltimore, MD). 2005;41:1179–97.CrossRefGoogle Scholar
  42. 42.
    Bohan TP, Helton E, McDonald I, Konig S, Gazitt S, Sugimoto T, Scheffner D, Cusmano L, Li S, Koch G. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001;56:1405–9.CrossRefGoogle Scholar
  43. 43.
    Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer. 2009;115:3189–95.CrossRefGoogle Scholar
  44. 44.
    Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1–28.CrossRefGoogle Scholar
  45. 45.
    Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res. 2009;39:427–31.CrossRefGoogle Scholar
  46. 46.
    Stickel F, Droz S, Patsenker E, Bogli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol. 2009;50:111–7.CrossRefGoogle Scholar
  47. 47.
    Hollister LE. Allergy to chlorpromazine manifested by jaundice. Am J Med. 1957;23:870–9.CrossRefGoogle Scholar
  48. 48.
    Ishak KG, Irey NS. Hepatic injury associated with the phenothiazines. Clinicopathologic and follow-up study of 36 patients. Arch Pathol. 1972;93:283–304.PubMedGoogle Scholar
  49. 49.
    Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointest Dis. 2001;12:113–24.PubMedGoogle Scholar
  50. 50.
    Watanabe N, Takashimizu S, Kojima S, Kagawa T, Nishizaki Y, Mine T, Matsuzaki S. Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis. Hepatol Res. 2007;37:598–607.CrossRefGoogle Scholar
  51. 51.
    Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother. 1994;33:387–401.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.New HampshireUSA
  2. 2.KyotoJapan

Personalised recommendations